Can EU-backed CDMO projects redefine pharma supply chains in post-industrial Europe?

By on    Features & Analysis  

Can EU-backed CDMO projects redefine pharma supply chains in post-industrial Europe?

The European Commission’s recent approval of €47 million in German state aid for Vetter Pharma’s new aseptic filling facility in Saarlouis marks more than a regional win. It signals a structural shift in how Europe views contract manufacturing organizations, or CDMOs—not merely as outsourcing vendors, but as core pillars of supply chain resilience, regional economic […]

Why are “retired proteins” the hottest new targets in cancer immunotherapy research?

By on    Features & Analysis  

Why are “retired proteins” the hottest new targets in cancer immunotherapy research?

Few ideas have captivated both the scientific imagination and biotech investment flows quite like the cancer vaccine. For decades, the industry narrative was full of hope—and disappointment. The graveyard of failed trials stretches from Dendreon’s Provenge to once-hyped peptide and dendritic cell platforms. For every announcement of an “immune breakthrough,” there seemed to be a […]

1 … 3 4 5